Results 11 to 20 of about 95,577 (390)
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts [PDF]
Annals of Neurology, 2018 Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal ...
A. Espay +9 more
semanticscholar +3 more sources
Cells, 2021 Dyskinesias are characterized by abnormal repetitive involuntary movements due to dysfunctional neuronal activity. Although levodopa-induced dyskinesia, characterized by tic-like abnormal involuntary movements, has no clinical treatment for Parkinson’s ...
Luca Pagliaroli +9 more
doaj +1 more source
Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
PLoS ONE, 2020 A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication.
Jin Yong Hong +6 more
doaj +1 more source
Levodopa-responsive chorea: A review
Annals of Indian Academy of Neurology, 2020 Background: Chorea is one of the disabling movement disorders, and the number of drugs which can treat this disorder effectively is limited. Tetrabenazine and deutetrabenazine are the two drugs approved by the US-FDA for the treatment of chorea ...
Mark Farrenburg, Harsh V Gupta
doaj +1 more source
npj Parkinson's Disease, 2023 The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen +6 more
doaj +1 more source
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Movement Disorders Clinical Practice, 2020 There has been a steadily growing armamentarium of drugs for the symptomatic treatment of Parkinson’s disease (PD). Consequently, as various various pharmaceutical agents are used, it has become more difficult to perform and compare clinical trials with ...
Sebastian Schade +2 more
semanticscholar +1 more source
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Frontiers in Neurology, 2021 Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios +9 more
doaj +1 more source
Cells, 2022 The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller +3 more
doaj +1 more source
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
npj Parkinson's Disease, 2021 Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed
Anouke van Rumund +8 more
doaj +1 more source
Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
Brain : a journal of neurology, 2020 See Poewe and Espay (doi:10.1093/brain/awaa226) for a scientific commentary on this article. Cilia et al. describe the natural course of motor symptoms in drug-naïve patients with Parkinson’s disease and the effects of long-term levodopa on motor ...
R. Cilia +11 more
semanticscholar +1 more source